NVAX - NASDAQ

Novavax, Inc.

NVAX·NASDAQ

$10.20

-2.9%

HealthcareBiotechnology

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.68B

EPS2.7200

P/E Ratio3.75

Earnings Date08/05/2026

1.18B

Assets

-25%

3Y-48.0%

5Y-26.0%

10Y+198.0%

1.30B

Total Liabilities

-40%

3Y-55.0%

5Y+37.0%

10Y+226.0%

-127.75M

Total Equity

-80%

3Y-80.0%

5Y-120.0%

10Y+2204.0%

Novavax, Inc. Funding & Solvency Profile

NVAX · NASDAQ

Current Assets

Cash & Cash Equivalents240.63M

Net Receivables106.45M

Inventory11.54M

Other Current Assets125.20M

Total Current Assets978 M

Non-Current Assets

Property, Plant & Equipment67.70M

Goodwill & Intangible Assets113.46M

Long-Term Investments0.00

Other Non-Current Assets17.08M

Total Non-Current Assets85 M

Total Assets

1.18B

Financial Health Analysis

Current Ratio

2.13x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Working Capital

518 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

83% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Novavax, Inc. Balance Sheet

NVAX • NASDAQ

Novavax, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	240.6M	530.2M	568.5M	1.3B	1.5B	553.4M	78.8M	70.2M	106.3M	144.4M	93.1M	32.3M	119.5M	17.4M	14.1M	8.1M	38.8M	26.9M	4.4M	7.2M
Short-Term Investments	494.5M	392.9M	0.0	0.0	0.0	157.6M	0.0	0.0	0.0	0.0	137.5M	135.7M	13.6M	26.7M	4.2M	23.6M	4.2M	7M	42.1M	66.4M
Cash & Short-Term Investments	735.1M	923.1M	568.5M	1.3B	1.5B	711M	78.8M	70.2M	106.3M	144.4M	230.7M	168.1M	133.1M	44.1M	18.3M	31.7M	43M	33.9M	46.5M	73.6M
Net Receivables	106.4M	108.3M	297.2M	82.4M	455M	262M	7.5M	0.0	0.0	233K	2.3M	10.6M	6.9M	2.6M	3.8M	54K	258K	290K	667K	2.1M
Accounts Receivables	106.4M	108.3M	297.2M	82.4M	455M	262M	7.5M	0.0	0.0	233K	2.3M	7.5M	1.9M	1M	2M	54K	258K	290K	667K	1.3M
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1M	5M	1.6M	1.8M	0.0	0.0	0.0	0.0	841K
Inventory	11.5M	8.7M	41.7M	36.7M	0.0	0.0	0.0	12M	13.1M	15.7M	0.0	0.0	4.5M	3.5M	2.4M	0.0	0.0	42K	25K	600K
Prepaids	0.0	56.3M	70.3M	160.8M	120M	171.6M	3.6M	12M	13.1M	15.7M	13M	7.6M	1.8M	1.6M	2.4M	1.6M	1.3M	774K	1.3M	979K
Other Current Assets	125.2M	32.5M	166.2M	86.7M	56.1M	103.5M	7.3M	3.2M	19.8M	20.6M	41.3M	1.9M	3.3M	2.1M	1.6M	1.6M	1.3M	90K	531K	53K
Total Current Assets	978.3M	1.1B	1.1B	1.7B	2.2B	1.2B	97.2M	119.3M	203.3M	287.8M	287.3M	188.2M	145M	50.4M	26.1M	33.3M	44.5M	35.1M	49M	77.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	67.7M	300M	491M	400.5M	228.7M	180M	11.4M	28.4M	36M	40.2M	32.3M	19.7M	14.3M	11.5M	6.9M	8.2M	7.8M	8.2M	5.7M	9.9M
Goodwill	113.5M	107.5M	127.5M	126.3M	131.5M	135.4M	51.2M	52M	53.6M	51.7M	53.1M	54.6M	59.5M	33.1M	33.1M	33.1M	33.1M	33.1M	33.1M	33.1M
Intangible Assets	0.0	0.0	0.0	0.0	4.8M	5.7M	5.6M	6.5M	7.9M	9.2M	10.8M	12.6M	16.3M	0.0	0.0	0.0	0.0	0.0	0.0	978K
Goodwill & Intangible Assets	113.5M	107.5M	127.5M	126.3M	136.2M	141.1M	56.7M	58.5M	61.4M	60.9M	63.9M	67.2M	75.8M	33.1M	33.1M	33.1M	33.1M	33.1M	33.1M	34.1M
Long-Term Investments	0.0	0.0	0.0	1.7M	1.7M	0.0	410K	958K	890K	4.6M	1.5M	0.0	0.0	6.2M	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	-1.7M	-1.7M	0.0	-410K	-958K	-890K	-4.6M	-1.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	17.1M	24M	35.2M	28.5M	56.7M	13.2M	7.5M	1.8M	1.8M	5.4M	2.6M	918K	916K	1.1M	469K	160K	160K	160K	3.4M	555K
Total Non-Current Assets	198.2M	431.5M	653.6M	555.3M	421.6M	334.3M	75.7M	88.7M	99.2M	106.5M	98.8M	87.8M	90.9M	51.9M	40.5M	41.5M	41.1M	41.5M	42.3M	44.5M
Total Assets	1.2B	1.6B	1.8B	2.3B	2.6B	1.6B	173M	208M	302.5M	394.3M	386M	276M	235.9M	102.3M	66.6M	74.8M	85.6M	76.6M	91.3M	121.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	24.6M	41.6M	132.6M	216.5M	127.1M	54.3M	2.9M	9.3M	5.6M	5.7M	11.9M	12.9M	6M	3.2M	2.6M	3.6M	2.1M	1.8M	1.5M	1.5M
Accounts Payable	24.6M	41.6M	132.6M	216.5M	127.1M	54.3M	2.9M	9.3M	5.6M	5.7M	11.9M	12.9M	6M	3.2M	2.6M	3.6M	2.1M	1.8M	1.5M	1.5M
Accrued Expenses	0.0	150.8M	338.7M	538.6M	635.3M	116.6M	7.5M	9.6M	11.2M	7.3M	11.3M	8.6M	5.1M	4M	2.3M	2.3M	5.4M	412K	1.6M	3.1M
Short Term Debt	2.5M	0.0	0.0	324.9M	0.0	0.0	0.0	0.0	0.0	0.0	395K	603K	877K	157K	20K	80K	80K	22.4M	1.1M	731K
Capital Lease Obligations (Current)	0.0	7M	5.1M	27.2M	130.5M	105.9M	1.3M	0.0	0.0	0.0	0.0	0.0	108K	58K	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	140.1M	675.1M	241.3M	370.1M	1.4B	273.2M	1.7M	10M	25.6M	30.1M	34.5M	2.5M	271K	258K	386K	0.0	432K	3.3M	3M	0.0
Other Current Liabilities	292.8M	279.9M	917.4M	982.6M	74.5M	29.6M	12.4M	16.6M	31.3M	23.3M	18.5M	10.9M	6.6M	3.9M	2.2M	4.3M	282K	3.1M	2M	0.0
Total Current Liabilities	460M	1.2B	1.6B	2.5B	2.4B	579.7M	25.8M	45.5M	73.7M	66.4M	76.5M	34.1M	18.9M	11.7M	7.6M	10.3M	8M	27.7M	6.2M	5.3M
NON-CURRENT LIABILITIES
Long Term Debt	246.3M	169.7M	168M	166.5M	323.5M	322M	320.6M	319.2M	317.8M	316.3M	0.0	395K	1M	753K	300K	320K	406K	480K	21.6M	22.5M
Deferred Revenue (Non-Current)	0.0	446.8M	622.2M	179.4M	172.5M	0.0	2.5M	2.5M	2.5M	2.5M	4.2M	2.5M	2.5M	2.5M	4.5M	0.0	2.7M	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.7M	8.5M	-237K	0.0	0.0	-2.7M	0.0	0.0	0.0
Other Non-Current Liabilities	598M	359.6M	33.1M	55.7M	42.1M	13.5M	10.1M	8.7M	10.3M	14.6M	12.7M	-6.1M	1.6M	6.9M	368K	5.2M	0.0	0.0	391K	79K
Total Non-Current Liabilities	844.3M	1B	879.3M	432.8M	538.1M	375.6M	333.2M	330.4M	330.6M	333.4M	16.9M	12.3M	13.8M	10.4M	5.1M	5.5M	3.1M	3.4M	22M	22.5M
Capital Lease Obligations	0.0	60.7M	61.1M	58.4M	130.5M	145.9M	1.3M	0.0	0.0	0.0	0.0	0.0	303K	295K	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	1.3B	2.2B	2.5B	2.9B	2.9B	955.3M	359M	375.9M	404.2M	399.8M	93.4M	46.4M	32.7M	22.1M	12.7M	15.8M	11.1M	31.1M	28.2M	27.9M
SHAREHOLDERS' EQUITY
Treasury Stock	-103M	-95.9M	-92.3M	-90.7M	-85.1M	-41.8M	-2.6M	-2.5M	-2.5M	-2.5M	-2.5M	-2.5M	-2.5M	-2.5M	-2.5M	-2.5M	-2.5M	-2.5M	-2.5M	-2.5M
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	191K	0.0	0.0	124K	0.0	161K	0.0	168K	228K	180K	0.0	0.0	0.0
Common Stock	1.7M	1.6M	1.4M	868K	764K	714K	324K	3.8M	3.2M	2.7M	2.7M	2.4M	2.1M	1.5M	1.2M	1.1M	1M	692K	624K	622K
Additional Paid-In Capital	4.5B	4.5B	4.2B	3.7B	3.4B	2.5B	1.3B	1.1B	1B	936M	951.6M	729.4M	612.9M	438.9M	383.9M	371.5M	350.8M	284.6M	264.6M	261.8M
Retained Earnings	-4.6B	-5B	-4.8B	-4.3B	-3.6B	-1.9B	-1.4B	-1.3B	-1.1B	-930M	-650M	-493.1M	-410.1M	-358.2M	-329.7M	-310.3M	-274.2M	-235.8M	-199.7M	-165M
Accumulated Other Comprehensive Income/Loss	2M	-22.6M	2.7M	-6.4M	-1.4M	7M	-12.5M	-11.2M	-8.6M	-11.8M	-9.1M	-6.6M	839K	430K	832K	772K	820K	-2M	-8.1M	-1M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.6M	-1.6M	0.0	0.0	0.0
Total Stockholders' Equity	-127.8M	-623.8M	-716.9M	-634.1M	-351.7M	627.2M	-186M	-167.9M	-101.7M	-5.5M	292.7M	229.6M	203.2M	80.2M	53.8M	59.1M	74.5M	45.5M	63.1M	94M
Total Equity	-127.8M	-623.8M	-716.9M	-634.1M	-351.7M	627.2M	-186M	-167.9M	-101.7M	-5.5M	292.7M	229.6M	203.2M	80.2M	53.8M	59.1M	74.5M	45.5M	63.1M	94M
SUMMARY
Total Liabilities & Equity	1.2B	1.6B	1.8B	2.3B	2.6B	1.6B	173M	208M	302.5M	394.3M	386M	276M	235.9M	102.3M	66.6M	74.8M	85.6M	76.6M	91.3M	121.9M
Total Investments	494.5M	392.9M	0.0	1.7M	1.7M	157.6M	410K	958K	890K	4.6M	139.1M	135.7M	13.6M	32.9M	4.2M	23.6M	4.2M	7M	42.1M	66.4M
Total Debt	248.8M	230.4M	229.1M	549.8M	454M	468M	321.9M	319.2M	317.8M	316.3M	395K	998K	2.2M	1.2M	320K	400K	486K	22.9M	22.7M	23.2M
Net Debt	8.2M	-299.8M	-339.4M	-787.1M	-1.1B	-85.4M	243.1M	249M	211.5M	172M	-92.7M	-31.3M	-117.3M	-16.2M	-13.8M	-7.7M	-38.3M	-4M	18.4M	16M
Shares Outstanding	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738	162,490,738

SEC Filings

NVAX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 27, 2026	June 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 20, 2026	January 15, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 03, 2025	2025	View Filing

Showing 1 to 10 of 549 filings

Related Guides

Blog Categories

Continue your NVAX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.